This underscores the clinical value of hs-cTnT in refining risk assessment for AF patients, particularly in the intermediate-risk group, potentially offering a more precise basis for decisions regarding anticoagulation therapy. This evidence concerns the gene TNNT2 and atrial fibrillation.